Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26475
Abstract: Steroid‐refractory (SR) acute graft‐versus‐host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the efficacy, safety, prognostic factors, and optimal therapeutic protocol for SR‐aGVHD… read more here.
Keywords: basiliximab; steroid refractory; refractory acute; acute graft ... See more keywords
#1006 Basiliximab induction alone vs. a dual ATG-basiliximab approach in first living non-sensitized renal transplant recipients with reduced HLA matching
Sign Up to like & getrecommendations! Published in 2025 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaf116.0803
Abstract: Individualizing induction therapy based on immunological risk is crucial for optimizing outcomes in kidney transplantation. Due to the prevalent utilization of living unrelated donor (LURD) transplants in Israel , a substantial proportion of non-sensitized recipients… read more here.
Keywords: non sensitized; basiliximab induction; hla matching; atg ... See more keywords
Assessment of immunosuppression induction with basiliximab compared to antithymocyte‐globulin in adult heart transplant patients
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Transplantation"
DOI: 10.1111/ctr.15332
Abstract: Patients undergoing heart transplants are at risk of rejection which can have significant morbidity and mortality. Induction immunosuppression at the time of transplant reduces the early risk and has additional benefits. The induction agent of… read more here.
Keywords: heart; antithymocyte globulin; immunosuppression; basiliximab ... See more keywords